Ivonescimab plus chemotherapy improves overall survival in patients with EGFR-variant nonsquamous NSCLC
Trial shows ivonescimab extends life for certain lung cancer patients
Researchers evaluated the addition of ivonescimab to pemetrexed and carboplatin chemotherapy for patients with advanced NSCLC who previously…
A new drug combination showed a significant improvement in survival rates for patients with specific types of advanced lung cancer.
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…